Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P07947

UPID:
YES_HUMAN

ALTERNATIVE NAMES:
Proto-oncogene c-Yes; p61-Yes

ALTERNATIVE UPACC:
P07947; A6NLB3; D3DUH1

BACKGROUND:
The Tyrosine-protein kinase Yes, identified by its aliases Proto-oncogene c-Yes and p61-Yes, is a non-receptor protein tyrosine kinase integral to regulating apoptosis, cytoskeleton remodeling, and cell differentiation. Activation by EGFR, PDGFR, and other RTKs triggers phosphorylation events that are crucial for cell growth and survival. YES1's role in phosphorylating OCT2, which enhances its transport activity, further illustrates its broad impact on cellular function.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Tyrosine-protein kinase Yes offers a promising avenue for drug discovery. Given its central role in mediating cell cycle progression and its involvement in G2/M progression, targeting YES1 could lead to innovative treatments for diseases characterized by uncontrolled cell growth, such as cancer.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.